(firstQuint)Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer.

 - Assess the safety and tolerance of a weekly MEDI 522 regimen in patients with irinotecan-refractory advanced CRC.

 - Determine a Phase II recommended dose based on acceptable dose-limiting toxicity.

 Other considerations such as pharmacokinetic parameters may also be factored into the determination of a Phase II dose.

 The secondary objectives of the study are to: - Assess any antitumor activity of MEDI-522 in this patient population.

.

 Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer@highlight

#NAME?